ZA200906648B - Pyrido [2,3-D] pyramidin-7-one compounds as inhibitors of P13K-alpha for the treatment of cancer - Google Patents

Pyrido [2,3-D] pyramidin-7-one compounds as inhibitors of P13K-alpha for the treatment of cancer

Info

Publication number
ZA200906648B
ZA200906648B ZA200906648A ZA200906648A ZA200906648B ZA 200906648 B ZA200906648 B ZA 200906648B ZA 200906648 A ZA200906648 A ZA 200906648A ZA 200906648 A ZA200906648 A ZA 200906648A ZA 200906648 B ZA200906648 B ZA 200906648B
Authority
ZA
South Africa
Prior art keywords
pyramidin
pyrido
inhibitors
cancer
alpha
Prior art date
Application number
ZA200906648A
Other languages
English (en)
Inventor
Chris A Buhr
Longcheng Wang
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of ZA200906648B publication Critical patent/ZA200906648B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/025—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus inorganic Tc complexes or compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA200906648A 2007-04-11 2009-09-23 Pyrido [2,3-D] pyramidin-7-one compounds as inhibitors of P13K-alpha for the treatment of cancer ZA200906648B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91116007P 2007-04-11 2007-04-11

Publications (1)

Publication Number Publication Date
ZA200906648B true ZA200906648B (en) 2010-04-28

Family

ID=39642739

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200906648A ZA200906648B (en) 2007-04-11 2009-09-23 Pyrido [2,3-D] pyramidin-7-one compounds as inhibitors of P13K-alpha for the treatment of cancer

Country Status (25)

Country Link
US (2) US20100209340A1 (es)
EP (1) EP2142544B8 (es)
JP (1) JP2010523681A (es)
KR (1) KR20090130104A (es)
CN (1) CN101711249A (es)
AU (1) AU2008239596B2 (es)
BR (1) BRPI0810175A2 (es)
CA (1) CA2683820A1 (es)
CO (1) CO6241119A2 (es)
CR (1) CR11098A (es)
DO (1) DOP2009000242A (es)
EA (1) EA018964B1 (es)
EC (1) ECSP099722A (es)
ES (1) ES2425068T3 (es)
IL (1) IL201209A0 (es)
MA (1) MA31336B1 (es)
MX (1) MX2009010815A (es)
MY (1) MY150747A (es)
NI (1) NI200900183A (es)
NZ (1) NZ579945A (es)
SV (1) SV2009003389A (es)
TN (1) TN2009000389A1 (es)
UA (1) UA101315C2 (es)
WO (1) WO2008127712A1 (es)
ZA (1) ZA200906648B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1828186A1 (en) * 2004-12-13 2007-09-05 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
HRP20130902T1 (hr) * 2005-10-07 2013-11-08 Exelixis Inc. PIRIDOPIRIMIDINONSKI INHIBITORI PI3Kalfa
AU2006302179C1 (en) * 2005-10-07 2013-06-20 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
CA2658725A1 (en) 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
AU2007297212B8 (en) * 2006-09-15 2011-04-28 Pfizer Products Inc. Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors
EA020022B1 (ru) 2007-04-10 2014-08-29 Экселиксис, Инк. Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k-альфа
CA2683784A1 (en) * 2007-04-11 2008-10-23 Exelixis, Inc. Pyrido[2,3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
JP2012504628A (ja) * 2008-09-30 2012-02-23 エグゼリクシス， インコーポレイテッド ＰＩ３ＫαおよびｍＴＯＲのピリドピリミジノン阻害剤
EP3309152B1 (en) * 2009-12-22 2020-09-09 Vertex Pharmaceuticals Incorporated Isoindolinone inhibitors of phosphatidylinositol 3-kinase
UY33221A (es) 2010-02-09 2011-09-30 Univ California MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA
WO2012037204A1 (en) 2010-09-14 2012-03-22 Exelixis, Inc. Inhibitors of pi3k-delta and methods of their use and manufacture
WO2013056067A1 (en) * 2011-10-13 2013-04-18 Exelixis, Inc. Compounds for use in the treatment of basal cell carcinoma
PH12014500973A1 (en) 2011-11-01 2014-06-16 Exelixis Inc Phosphatidylinositol 3-kinase inhibitors for the treatment of lymphoproliferative malignancies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2937284A (en) * 1958-05-01 1960-05-17 Burroughs Wellcome Co 2, 4-diamino-5, 6-dialkylpyrido (2, 3-d) pyrimidines and method
IL117923A (en) * 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US7019002B2 (en) * 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
DE602005002562T2 (de) * 2004-05-04 2008-01-31 Warner-Lambert Company Llc Pyrrolylsubstituierte pyridoä2,3-düpyrimidin-7-one und derivate davon als therapeutische mittel
HRP20130902T1 (hr) * 2005-10-07 2013-11-08 Exelixis Inc. PIRIDOPIRIMIDINONSKI INHIBITORI PI3Kalfa
WO2007044698A1 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
CA2658725A1 (en) * 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
AU2007297212B8 (en) * 2006-09-15 2011-04-28 Pfizer Products Inc. Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors

Also Published As

Publication number Publication date
SV2009003389A (es) 2010-04-27
CN101711249A (zh) 2010-05-19
ES2425068T3 (es) 2013-10-11
HK1139941A1 (en) 2010-09-30
UA101315C2 (ru) 2013-03-25
BRPI0810175A2 (pt) 2014-12-30
EP2142544A1 (en) 2010-01-13
MY150747A (en) 2014-02-28
KR20090130104A (ko) 2009-12-17
AU2008239596A1 (en) 2008-10-23
US20100209340A1 (en) 2010-08-19
NZ579945A (en) 2012-05-25
CA2683820A1 (en) 2008-10-23
EP2142544B1 (en) 2013-05-22
US20130343988A1 (en) 2013-12-26
MX2009010815A (es) 2009-10-29
NI200900183A (es) 2010-10-05
ECSP099722A (es) 2009-12-28
EA018964B1 (ru) 2013-12-30
TN2009000389A1 (en) 2010-12-31
DOP2009000242A (es) 2010-04-30
CR11098A (es) 2010-01-27
JP2010523681A (ja) 2010-07-15
IL201209A0 (en) 2010-05-31
AU2008239596B2 (en) 2013-08-15
CO6241119A2 (es) 2011-01-20
EA200970936A1 (ru) 2010-02-26
MA31336B1 (fr) 2010-04-01
EP2142544B8 (en) 2013-07-03
WO2008127712A1 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
IL201209A0 (en) Pyrido [2, 3 - d] pyrimidin - 7 - one compounds as inhibitors of pi3k - alpha for the treatment of cancer
EP2142543B8 (en) Pyrido [2, 3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
ZA201104853B (en) 2,5-diamino-substituted pyrido[4,3-d]pyrimidines as autotaxin inhibitors against cancer
PT2303021T (pt) Compostos para tratamento do cancro
HUE059861T2 (hu) N-Szubsztituált 2,5-dioxo-azolin vegyületek a rák kezelésében való felhasználásra
IL211193A0 (en) Bicyclic triazole derivatives for the treatment of tumours
AP2010005508A0 (en) Triazole derivatives useful for the treatment of diseases.
IL191832A0 (en) Pyridiazinone derivatives for the treatment of tumours
IL202505A0 (en) 2-oxo-3-benzyl-benzoxazol-2-one derivatives and related compounds as met kinase inhibitors for the treatment of tumors
ZA200903533B (en) Process for the preparation of rosuvastatin
SI2124944T1 (sl) Derivati pirazolo b piridina kot inhibitorji fosfodiesteraze
ZA201003425B (en) 5-cyano-thienopyridines for the treatment of tumors
IL211313A0 (en) Compounds, compositions and methods for the treatment of ??-amyloid diseases and synucleinopathies
IL210074A (en) Process for the preparation of pyrido derivatives [2, 3 – d] pyrimidine-7-il-phenyl
ZA201005116B (en) 6.7-dialkoxy ouinazoline derivatives useful for treatment of cancer related disorders
ZA200909132B (en) 6-Phenyl-1H-Imidazo[4,5-C]Pyridine-4-Carbonitrile derivatives as cathepsin inhibitors
IL205082A0 (en) Process for the preparation of tetranorlabdane derivatives
IL210066A0 (en) Novel ortho-aminoanilides for the treatment of cancer
IL206189A0 (en) Compound for use in the treatment of cancer
GB2464854B (en) Process for the preparation of risperidone
ZA201303580B (en) Oxazolo [5,4-b]pyridin-5-yl compounds and their use for the treatment of cancer
IL226362A0 (en) compounds, and methods for treating cancer
ZA201003264B (en) Method for the preparation of 2 chloro1,1,1,2,3,3,3 heptafluopropane
GB2476644B (en) 1,4-Dihydro-1,4-dioxonaphtalene derivatives for the treatment of osteoporosis
AU2007901333A0 (en) Method for the treatment of cancer